Fosun is pulling back from the U.S. biotech sector in response to the escalating trade war with China. The Chinese conglomerate has struck deals with Kite Pharma, Revance Therapeutics and other U.S. biotechs in the past but now plans to limit its activities in the country.
Talking to Bloomberg, Kevin Xie, who oversees Fosun’s healthcare investments outside of China, set out how the standoff between government leaders at the two global powers has affected his work.
“Trade friction has impacted our investments in the U.S., but not to the extent of stopping all deals,” Xie said. “Companies in the U.S. still welcome investments and are willing to work with us, so we are making some changes in the wiggle room allowed under the law.”
Fosun’s difficulties stem from a shift in the position of the Committee on Foreign Investment in the United States (CFIUS). Under President Donald Trump, CFIUS has intensified its assessments of the national security implications of the takeovers of domestic assets and extended its reach beyond M&A.
Notably, in August CFIUS gained the power to screen certain foreign venture capital transactions and to restrict the licensing and transfer of technologies. The full impact of the new powers will only become clear as key details about its implementation, such as the technologies the restrictions apply to, are worked out. But the initial impact has been big enough to persuade Fosun to shift focus from the U.S.
If other Chinese investors follow Fosun’s lead, the U.S. biotech sector will lose access to a significant source of investment. Last year, Chinese investors struck U.S. healthcare deals worth $2.8 billion, up from around $700 million the previous year.
The surge in the outbound activity of Chinese investors and biopharma companies has provided U.S. with money and overseas partners. And U.S. VCs have secured money from Fosun and other Chinese players, too.
By Nick Paul Taylor
Source: Fierce Biotech
Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.
The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.
Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.